The deadline to file a securities fraud lawsuit against AstraZeneca PLC (AZN) is February 21, 2025.
NEW YORK – January 11, 2025 (NEWMEDIAWIRE) – Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against AstraZeneca PLC (LON: ) (AstraZeneca (NASDAQ: ) or the Company) (NASDAQ: AZN ) on behalf of investors who purchased or otherwise acquired AstraZeneca securities, including American Depositary Shares (ADS), between February 23, 2022 and December 17, 2024. (Class period).
CLICK HERE TO JOIN THE CASE
If you are an investor in AstraZeneca and have suffered losses, you can CLICK HERE to contact us. You can also contact Kaplan Fox by emailing pmayer@kaplanfox.com or calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed class, you may move the court no later than February 21, 2025 to be the lead plaintiff for the proposed class. If you have losses, we encourage you to contact us to learn more about the Attorney General process.
On February 22, 2022, at the beginning of the Class Period, AstraZeneca filed its annual report with the SEC, which included a disclosure of risks that [a]ny non-compliance with these [worldwide] applicable laws, rules and regulations may result in AstraZeneca being investigated by relevant government authorities. . . .
On October 30, 2024, AstraZeneca made an announcement on its website that Leon Wang, Executive Vice President International and President of AstraZeneca China was under investigation by Chinese authorities.
Following this news, the price of AstraZeneca ADSs fell $2.39 per share, or about 3.2%, to $72.83 per share on October 30, 2024.
On November 5, 2024, Yicai Global published an article reporting on this [d]dozens of senior executives at AstraZeneca China have been implicated in an ongoing insurance fraud case since last week, according to a person familiar with the matter.
Following this news, the price of AstraZeneca ADSs fell $5.16 per share, or about 7.2%, to $66.27 per share on November 5, 2024.
Then on December 18, 2024, the Financial Times published an article titled AstraZeneca Insiders Expect Sales to Fall in China After Arrest of Local Boss, reporting that AstraZeneca China President Leon Wang had been arrested.
Following this news, the price of AstraZeneca ADSs fell $2.54 per share, or about 3.8%, to $64.64 per share on December 18, 2024.
WHY CONTACT KAPLAN FOX – Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and results clients demand. Through litigating cases at the federal and state levels, Kaplan Fox has successfully shaped the law by making many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you can visit our website at www.kaplanfox.com.
This press release may be considered solicitor advertising in some jurisdictions under applicable law and ethical rules.
If you have any questions about this Notice, your rights or interests, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
See the original release at www.newmediawire.com
Copyright 2025 JCN Newswire. All rights reserved.
